Nykode Therapeutics As (VACBF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Nykode Therapeutics Q2 twenty twenty six Financial Results Presentation. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. You may ask a question at any time by typing it into the ask a question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to CEO, Michael Nykode. Please go ahead, sir. Thank you very much, Kevin, and also from our side, a very warm welcome and good morning to all participants on this quarterly results presentation. We assume you are familiar with our forward looking statements. And on that note, we'll move forward. As usual, I am very pleased to have with me here today, Nykode Frederiksen, our Co Founder, Chief Scientific Officer and Head of Business Development as well as Harald Groen, our CFO. For those not familiar with Nykode, just a few words on the company. Nykode is a clinical stage immunotherapy company with a focus on oncology and autoimmune diseases. Our lead asset is abezuga, a therapeutic cancer vaccine targeted against HPV16 driven cancer types. We have encouraging results across three different indication three trials with close to 100 patients in total, which gave us the confidence to move into the first randomized Phase II trial in first line head and neck, which is ongoing and called ability on track to deliver the first interim results in 2027. Our second clinical asset is Vipizen neo, which is an individualized neoantigen therapy. We saw some very important validating results from the field last week, and we'll, of course, be discussing that more in-depth at this call here. We have clinical data from, Vipizen neo, from more than 10 tumor types. And based on th...